Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92).
Recombinant interleukin (IL)-4, 5 μg/kg thrice weekly for 3 weeks followed by a 2-week rest period (1 cycle) was administered to 32 eligible previously treated B-cell chronic lymphocytic leukemia (7 patients) or low-grade B-cell lymphoma patients (25 patients). Two cycles were given before response was evaluated. IL-6 serum levels were evaluated before therapy in all patients and at 12 weeks on study in 7 patients. None of the chronic lymphocytic leukemia patients responded. A partial response was observed in 3 lymphoma patients of 1.2, 3.0, and 3.5 months' duration and stable disease (median 1.5 mo) was observed in another 7 lymphoma patients. The median survival from registration on study was 29.7 months with 7 patients alive at the time of analysis for a median follow-up of 72.8 months. Toxicity was generally mild with no grade 4 nonhematologic toxicity observed. Recombinant IL-4 treatment was well tolerated in this study but had minimal antitumor activity.
New York Medical College, Valhalla, NY, USA.
Peter H
PH
Wiernik
Janice P
JP
Dutcher
Xiapan
X
Yao
Usha
U
Venkatraj
Carla I
CI
Falkson
Jacob M
JM
Rowe
Peter A
PA
Cassileth
D000328:Adult; D000368:Aged; D005500:Follow-Up Studies; D006801:Humans; D015847:Interleukin-4 / Q000008:administration & dosage* / Q000009:adverse effects; D015850:Interleukin-6 / Q000097:blood; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000009:adverse effects; D016019:Survival Analysis; D017211:Treatment Failure; D016896:Treatment Outcome
D015850:Interleukin-6; D011994:Recombinant Proteins; D015847:Interleukin-4